|
Indian Pediatr 2020;57: 798-800 |
|
Urinary Intestinal Fatty Acid Binding
Protein for Diagnosis of Necrotizing Enterocolitis
|
Amarnath Saran 1,
Devananda Devegowda2
And Srinivasa Murthy Doreswamy1
From Departments of 1Pediatrics and 2Biochemistry,
JSS Medical College, JSS Academy of Higher Education and
Research, Mysuru, Karnataka, India.
Corresponding to: Dr Srinivasa Murthy Doreswamy,
Professor in Pediatrics, JSS Medical College, JSS Academy of
Higher Education and Research, Mysuru 570001, Karnataka,
India. [email protected]
Submitted: February 10, 2019;
Initial review: June 10, 2019;
Accepted: April 05, 2020.
Published online: June 12, 2020; PII:
S097475591600193
|
Objective: This study
was conducted to compare the urinary levels of intestinal fatty
acid binding protein (I-FABP) and I-FABP: Cr (creatinine)
between neonates with necrotising enterocolitis and gestation
matched healthy controls. Methods: 24 neonates with stage
1, 25 with stage 2 and 3 necrotizing enterocolitis, and 25
gestation matched (32.9 wk) controls were compared. Single spot
urine sample was collected for estimating the IFABP and
creatinine levels. Results: Median (IQR) value of urinary
I-FABP were higher in those with stage 2, 3 NEC [2773 (2417.7-
2820)] than stage 1 NEC [1164 pg/mL (1341.5 – 2213.4)] and
controls [413 (113 – 729.7); pg/mL] (P<0.001). Urinary I-FABP:
Cr levels of 3.6 pg/mmoL had a sensitivity and specificity of
96% and 99.5%, respectively in diagnosing stage 2/3 NEC.
Conclusion: Urinary IFABP: Creatine ratio of 3.6 pg/mmoL is
highly specific for stage 2 and 3 NEC.
Key words: Diagnostic marker,
Necrotizing enterocolitis. Newborn, Bell criteria, Preterm
|
N ecrotizing enterocolitis (NEC) has a
reported incidence of 5-10% in very low birth weight babies
[1]. Clinical signs and abdominal X-ray in early
stages are nonspecific, resulting in a diagnostic challenge.
Intestinal fatty acid binding protein
(I-FABP) is a sensitive and specific biochemical marker for
NEC [2-5]. I-FABP is an intestinal mucosal protein, which
escapes into circulation upon enterocyte injury in trauma,
infection or ischemia [7-9]. It gets filtered into urine
which can be measured to compare the urinary levels of
I-FABP and I-FABP clearance between neonates with suspected
NEC and gestation matched controls.
Methods
This study was conducted in a tertiary
care unit in India between February, 2015 and December,
2016. Both preterm and term babies with NEC as per modified
Bell’s criteria were included as cases. Asymptomatic babies
with corrected gestational age within 3 days of the cases
formed the control group. Babies with surgical problems and
cyanotic heart disease were excluded.
Cases were recruited separately in two
groups, suspected (stage 1) NEC and established (stage 2 and
3) NEC, for a single control. This study was approved by
institutional ethics board. Informed written consent was
taken from the parents prior to obtaining urine sample.
Five milliliters of urine sample was
collected within 12 hours of diagnosis and stored after
centrifugation at –80°C under sterile condition. Sample from
an appropriate control was collected and similarly stored.
Human I-FABP was quantified using commercially available
enzyme linked immunosorbent assay (ELISA) (Hycult Biotech,
the Netherlands). Urinary creatinine (Cr) was measured at
the same time for estimation of I-FABP: Cr. The incidence of
NEC in our unit was 3.7%. Considering specificity of 94% and
alpha error of 5%, a total of 75 subjects were needed.
Statistical analysis: Statistical
analysis was done using Microsoft Excel 2016 and Analyse-it
v4.65.2. Kruskal Wallis test was used to compare the medians
and chi-square for proportions. ROC curve was plotted to
calculate the sensitivity and specificity of the test.
RESULTS
A total of 74 babies (25 control group,
24 with suspected NEC group and 25 with established NEC)
were recruited. Two babies were of 38 weeks gestation and
rest were preterms. The baseline characteristics are
depicted in Table I. Ten babies (6 with
established NEC) received CPAP/ventilator support and none
had birth asphyxia.
Table I Baseline Characteristics of the Study Population
|
Control
|
Suspected
|
NEC stage 2
|
|
(n=25) |
NEC (n=24) |
or 3(n=25) |
#Gestation (wk)
|
32.9 (2.3) |
32.8 (2.3) |
32.9 (2.3) |
*Birthweight (kg) |
1.7 |
1.56 |
1.54 |
|
(1.45-1.9) |
(1.36-1.89) |
(1.17-1.81) |
Male, n (%)
|
14 (56) |
13 (54.2) |
18 (72) |
Breast milk
|
23 (92) |
24 (100) |
24 (96) |
Normal delivery |
9 (36) |
6 (25) |
9 (36) |
P>0.05 for all inter-group comparisons; All
values in no. (%) except #mean (SD) *median (IQR). |
Median (IQR) urinary I-FABP value and
urinary IFABP: Cr in various groups is depicted in
Table II. Urinary IFABP value of 900 pg/mL had a
sensitivity of 91.8% and specificity of 92% in diagnosing
stage 1 NEC and a value of 1800pg/mL had a sensitivity of
88% and specificity of 82% in diagnosing stage 2 and stage 3
NEC.
Table II Urinary I-FABP levels and I-FABP: Creatinine in Neonates with Necrotizing Enterocolitis (N=74)
|
Control (n=25) |
Suspected NEC stage 1(n=24) |
NEC 2 or 3 (n=25) |
Urinary IFABP, pg/mL
|
413 (113-729.7) |
1164 (1341.5-2213.4) |
2773 (2471.7-2820) |
Urinary IFABP: Creatine, pg/mmoL |
1.23 (0.56-1.57) |
2.78 (2.32-3.36) |
4.84 (4.67-5.34) |
Data in median (IQR); I-FABP: intestinal fatty
acid bindings protein; data in median (IQR); P<0.001
for inter group comparisons. |
Urinary I-FABP: Cr ratio of 2.1pg/mL had
a sensitivity of 83.3% (95% CI 66.4, 95.3%) and specificity
of 96% (95% CI 87, 99.8%) for the diagnosis of stage 1 NEC.
True positive rate, true negative rate, positive likelihood
ratio and negative likelihood ratio were 91.8% (79.5-97.3%),
96% (77%-99.7%), 11.3 (4.4-28.9), 0.04(0.006-0.28),
respectively. A higher ratio of 3.6 pg/mmoL had a
sensitivity of 96% (95% CI 69.7, 97%) and specificity of
99.5% (95% CI 87.2, 99.8%) for diagnosis of stage 2 and 3
NEC; area under the curve was 0.99%. True positive rate,
true negative rate, positive likelihood ratio and negative
likelihood ratio were 96% (77.6-99.7%), 93.8% (82-98.4%), 24
(3.5-164), 0.06 (0.02-0.19), respectively.
DISCUSSION
A reliable marker for intestinal injury
can be helpful in clinically challenging situations. Our
study showed a significant increase in urinary excretion of
I-FABP in babies with NEC.
Several earlier studies have shown that
both plasma and urinary I-FABP are useful markers in
neonatal NEC [8-13]. Serial urinary and plasma IFABP values
predicted the progression and complication within 8 to 16
hours after onset of symptoms, and the highest level was
seen by 24 hours [8]. Neonates with higher baseline values
had developed NEC unlike others with lower values [11].
Urine I-FABP levels were also found
specifically elevated in NEC and not in sepsis [14]. A
urinary IFABP value of 1000 pg/mL was found to have a
sensitivity of 100% and specificity of 83% for diagnosis of
bowel ischemia [15], similar to our study.
Earlier studies have reported cut-off
values of IFABP: Cr ratio ranging from 2 to 5 pg/mmoL for
diagnosis of NEC [19,14]. The variations in cut-off values
is due to different priorities regarding sensitivity and
specificity, and the sample size. Our study showed high
specificity, and has good sensitivity for urine IFABP: Cr
level of 3.6 pg/mmoL for stage 2 and 3 NEC. As diagnostic
tests are done on clinical suspicion, even if the pre test
probability is about 50%, the post test probability would be
greater than 98%.
The present study did not prospectively
collect data with regard to respiratory support, sepsis or
asphyxia, which may be considered as a study limitation.
To conclude, urinary I-FABP is
significantly elevated in neonates with NEC. Urinary I-FABP:
Creatine ratio performed better than urinary I-FABP alone
for diagnosis of NEC and can serve as a quantitative marker
for assessment of severity of the illness.
Contributors: Contributors: AS:
recruited the subjects, collected the data, carried out
literature review and prepared the initial draft of
manuscript; DD: conducted the biochemical test and
contributed to manuscript writing; SMD: conceived and
designed the study, analyzed the data, and finalized the
manuscript. All authors have approved the manuscript
submitted.
Funding: None; Competing interests:
None stated.
What This Study Adds
• Raised urinary intestinal fatty
acid binding protein (I-FABP) and I-FABP: Creatinine
ratio are sensitive and specific for the diagnosis
of necrotizing enterocolitis in neonates.
|
REFERENCES
1. Muller MJ, Paul T, Seeliger S.
Necrotizing enterocolitis in premature infants and newborns.
J Neonatal Perinatal Med. 2016;9:233-42.
2. Reisinger KW, Van der Zee DC, Brouwers
HA, Kramer BW, van Heurn LW, Buurman WA, et.al.
Noninvasive measurement of fecal calprotectin and serum
amyloid – A combined with intestinal fatty acid-binding
protein in necrotizing enterocolitis. J Pediatr Surg.
2012;47:1640-5.
3. Funaoka H, Kanda T, Fujii H.
Intestinal fatty acid-binding protein (I-FABP) as a new
biomarker for intestinal diseases. Rinsho Byori.
2010;58:162-8.
4. Yang G, Wang Y, Jiang X. Diagnostic
value of intestinal fatty-acid-binding protein in
necrotizing enterocolitis: A systematic review and
meta-analysis. Indian J Pediatr. 2016;83:1410-9.
5. Aydemir C, Dilli D, Oguz SS, Ulu HO,
Uras N, Erdeve O, et.al. Serum intestinal fatty acid
binding protein level for early diagnosis and prediction of
severity of necrotizing enterocolitis. Early Hum Dev.
2011;87:659-61.
6. Smathers RL, Petersen RD. The human
fatty acid-binding protein family: Evolutionary divergences
and functions. Human Genomics. 2011;5;170-91.
7. Bingold TM, Franck K, Holzer K,
Zacharowski K, Bechstein WO, Wissing H, et.al.
Intestinal fatty acid binding protein: A sensitive marker in
abdominal surgery and abdominal infection. Surg Infect (Larchmt).
2015;16:247-53.
8. Schurink M, Kooi EM, Hulzebos CV, Kox
RG, Groen H, Heineman E, et.al. Intestinal fatty
acid-binding protein as a diagnostic marker for complicated
and uncomplicated necrotizing enterocolitis: A prospective
cohort study. PLoS One. 2015;10:e0121336.
9. Evennett NJ, Hall NJ, Pierro A, Eaton
S. Urinary intestinal fatty acid-binding protein
concentration predicts extent of disease in necrotizing
enterocolitis. J Pediatr Surg. 2010;45:735-40.
10. Gregory KE, Winston AB, Yamamoto HS,
Dawood HY, Fashemi T, Fichorova RN, et.al. Elevated
urinary I-FABP predicts necrotizing enterocolitis within
seven days prior to clinical onset. J Pediatr.
2014;164:1486-8.
11. Derikx JP, Evennett NJ, Degraeuwe PL,
Mulder TL, van Bijnen AA, van Heurn LW, et.al. Urine
based detection of intestinal mucosal cell damage in
neonates with suspected necrotising enterocolitis. Gut.
2007;56:1473-5.
12. Thuijls G, van Wijck K, Grootjans J,
Derikx JP, van Bijnen AA, Heineman E, et al. Early
diagnosis of intestinal ischemia using urinary and plasma
fatty acid binding proteins. Ann Surg. 2011; 253:303-8.
13. Thuijls G, Derikx JP, van Wijck K,
Zimmermann LJ, Degraeuwe PL, Mulder TL, et.al.
Non-invasive markers for early diagnosis and determination
of the severity of necrotizing enterocolitis. Ann
Surg.2010;251: 1174-80.
14. Coufal S, Kokesova A,
Tlaskalova-Hogenova H, Snajdauf J, Rygl M, Kverka M. Urinary
intestinal fatty acid-binding protein can distinguish
necrotizing enterocolitis from sepsis in early stage of the
disease. J Immunol Res. 2016;2016:5727312.
15. Cronk DR, Houseworth TP, Cuadrado DG, Herbert GS,
McNutt PM, Azarow KS. Intestinal fatty acid binding protein
(I-FABP) for the detection of strangulated mechanical small
bowel obstruction. Curr Surg.2006; 63:322-5.
|
|
|
|